Tarsus Pharmaceuticals, Inc.
TARS
Rankning i aktier
#4493
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Aktiekurs
$72.81
Marknadsvärde
$3.41B
Förändring (1 dag)
3.28%
Förändring (1 år)
5.99%
Land
US
Handel Tarsus Pharmaceuticals, Inc. (TARS)
Kategori
Healthcare
Aktiekurshistorik för Tarsus Pharmaceuticals, Inc. (TARS)
Högsta slutkurs: $72.28 den 2026-10-01
Lägsta slutkurs: $21.51 den 2020-10-01
Lägsta slutkurs: $21.51 den 2020-10-01
Aktiekurshistorik för Tarsus Pharmaceuticals, Inc. från 2020 till 2026
Årlig aktiekursutveckling
| År | Prestanda |
|---|---|
| 2026 (TTM) | -13.74% |
| 2025 | 54.26% |
| 2024 | 182.67% |
| 2023 | 21.69% |
| 2022 | -38.83% |
| 2021 | -32.39% |
| 2020 | 0.00% |
Aktiekurs för liknande företag eller konkurrenter
| Företag | Aktiekurs | Förändring 1år% | Land |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
